Michael F MacLean
CIK 1383731 · Chief Financial Officer · last filed 2026-04-03
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO, CA 92121
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CAMP | Director | — | $3.46 | — | $0 | 1 | 2026-04-03 |
| Avidity Biosciences, Inc. (RNAM) Delisted | Chief Financial Officer | 0 | — | — | $0 | 1 | 2026-02-27 |
| RNA | Chief Financial Officer | 62,025 | $8.28 | $513.6K | -$15.13M | 18 | 2026-01-23 |
| Verve Therapeutics, Inc. (VERV) Delisted | Director | — | $11.13 | — | $0 | 7 | 2025-07-28 |
| AKCEA THERAPEUTICS, INC. (AKCA) Delisted | Chief Financial Officer | 48,000 | — | — | $0 | 6 | 2020-01-16 |
| BIIB | SVP, Chief Accounting Officer | 10,681 | $249.52 | $2.67M | -$1.52M | 21 | 2010-10-04 |
Recent Filings · Page 5 of 6
59 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-04-20 | BIIB | Sell (S) | −3,757 | -$225.4K | EDGAR |
| 2010-03-23 | BIIB | Sell (S) | −4,085 | -$245.1K | EDGAR |
| 2010-02-25 | BIIB | Mixed | +3,140 | -$47.0K | EDGAR |
| 2010-02-17 | BIIB | Tax (F) | −2,002 | -$110.5K | EDGAR |
| 2010-01-19 | BIIB | Sell (S) | −1,389 | -$76.4K | EDGAR |
| 2009-11-03 | BIIB | Mixed | +582 | -$17.6K | EDGAR |
| 2009-10-05 | BIIB | Tax (F) | −953 | -$47.0K | EDGAR |
| 2009-02-26 | BIIB | Grant (A) | +4,030 | $0 | EDGAR |
| 2009-02-17 | BIIB | Tax (F) | −2,007 | -$105.6K | EDGAR |
| 2008-11-04 | BIIB | Mixed | +682 | -$13.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.